Skip to main content
SpringerLink
Log in

Update on Use of Biologic and Targeted Synthetic Drugs in Pregnancy

  • Chapter
  • First Online:
Women's Health in Autoimmune Diseases

Abstract

The availability of biologic disease modifying anti-rheumatic drugs (bDMARDs) and the development of targeted synthetic (ts)DMARDs has led to a new treatment era for patients with inflammatory rheumatic disease (IRD). The advent of these therapies has multiplied the number of therapeutic options available to induce remission and thus improved opportunities for women with previously poorly controlled disease activity to consider pregnancy during low disease activity states. These IRDs include systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis. Many of these conditions occur in women of reproductive age, and require use of traditional DMARDs and/or targeted biologic drugs to control and suppress active disease. Numerous studies have identified that women with IRD, particularly SLE, have an increased risk of experiencing adverse pregnancy outcomes (APOs), such as miscarriages, premature delivery, maternal hypertension or intrauterine growth restriction. The management of pregnancy in women with IRD is complicated by factors relating to disease, pregnancy, medication and patient concerns. Therefore, appropriate pre-pregnancy counselling and monitoring by a multidisciplinary team of obstetric and rheumatology specialists during pregnancy is essential to ensure that optimal control of maternal disease activity is achieved by appropriate use of compatible DMARDs before and during pregnancy, to enhance the chance for women with IRD to have successful pregnancy outcomes. In this chapter we aim to summarise and update current British and European evidence-based guidance on prescribing of bDMARDs and tsDMARDs during pregnancy and breastfeeding.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber K et al (2016) BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. In: Rheumatology (Oxford), vol 55, p 1693

    Google Scholar 

  2. Skorpen CG, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C et al (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75:795–810

    CAS  Google Scholar 

  3. Borella E, Lojacono A, Gatto M, Andreoli L, Taglietti M, Iaccarino L et al (2014) Predictors of maternal and fetal complications in SLE patients: a prospective study. Immunol Res 60(2–3):170–176

    CAS  PubMed  Google Scholar 

  4. Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, De Jesus GR, Erkan D (2013) Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res 65(11):1869–1873

    CAS  Google Scholar 

  5. Chakravarty EF, Nelson L, Krishnan E (2006) Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 54:899

    PubMed  Google Scholar 

  6. De Man YA, Dolhain RJEM, Van De Geijn FE, Willemsen SP, Hazes JMW (2008) Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Care Res 59:1241–1248

    Google Scholar 

  7. Clowse MEB, Magder LS, Witter F, Petri M (2005) The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 52(2):514–521

    PubMed  Google Scholar 

  8. Giles I, Yee C-S, Gordon C (2019) Stratifying management of rheumatic disease for pregnancy and breastfeeding. Nat Rev Rheumatol 15:391

    PubMed  Google Scholar 

  9. Nguyen H, Giles I (2016) Biologic disease modifying anti-rheumatic drugs in pregnancy and breast-feeding period. In: Ciurtin C, Isenberg DA (eds) Biologics in rheumatology: new developments, clinical uses and health implication. Nova Science Publisher, New York, pp 377–403

    Google Scholar 

  10. Mariette X, Förger F, Abraham B, Flynn AD, Moltó A, Flipo RM et al (2018) Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis 77(2):228–233

    CAS  PubMed  Google Scholar 

  11. Clowse MEB, Feldman SR, Isaacs JD, Kimball AB, Strand V, Warren RB et al (2016) Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis. Drug Saf 39(8):755–762

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Ostensen M, Lockshin M, Doria A, Valesini G, Meroni P, Gordon C et al (2008) Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology 47(Suppl 3):iii28–iii31

    PubMed  Google Scholar 

  13. Rawla P, Sunkara T, Raj JP (2018) Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives. J Inflamm Res 11:215–226

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Lovell DJ, Giannini EH, Reiff AO, Kimura Y, Li S, Hashkes PJ et al (2013) Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum 65(9):2486–2496

    CAS  PubMed  Google Scholar 

  15. Giunta A, Ventura A, Chimenti MS, Bianchi L, Esposito M (2017) Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy. Drug Des Devel Ther 11:1643–1651

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Hyrich KL, Verstappen SMM (2014) Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford) 53(8):1377–1385

    CAS  Google Scholar 

  17. Garty BZ, Ludomirsky A, Danin YL, Peter JB, Douglas SD (1994) Placental transfer of immunoglobulin G subclasses. Clin Diagn Lab Immunol 1(6):667–669

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M (2012) IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012:1

    Google Scholar 

  19. Nesbitt A, Kevorkian L, Baker T (2014) Lack of FcRn binding in vitro and no measurable levels of ex vivo placental transfer of certolizumab pegol. Hum Reprod 29:i127

    Google Scholar 

  20. Clowse ME, Förger F, Hwang C, Thorp J, Dolhain RJ, Van Tubergen A et al (2017) Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis 76(11):1890–1896

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Porter C, Armstrong-Fisher S, Kopotsha T, Smith B, Baker T, Kevorkian L et al (2016) Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. J Reprod Immunol 116:7–12

    CAS  PubMed  Google Scholar 

  22. Rowan CR, Cullen G, Mulcahy HE, Keegan D, Byrne K, Murphy DJ et al (2018) Ustekinumab drug levels in maternal and cord blood in a woman with Crohn’s disease treated until 33 weeks of gestation. J Crohns Colitis 12(3):376–378

    PubMed  Google Scholar 

  23. Friedrichs B, Tiemann M, Salwender H, Verpoort K, Wenger MK, Schmitz N (2006) The effects of rituximab treatment during pregnancy on a neonate. Haematologica 91:1426–1427

    PubMed  Google Scholar 

  24. Egawa M, Imai K, Mori M, Miyasaka N, Kubota T (2017) Placental transfer of canakinumab in a patient with muckle-wells syndrome. J Clin Immunol 37(4):339–341

    PubMed  Google Scholar 

  25. Murashima A, Watanabe N, Ozawa N, Saito H, Yamaguchi K (2009) Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant’s serum. Ann Rheum Dis 68(11):1791–1793

    Google Scholar 

  26. Berthelsen BG, Fjeldsøe-Nielsen H, Nielsen CT, Hellmuth E (2010) Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology 49(11):2225–2227

    CAS  PubMed  Google Scholar 

  27. Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J et al (2016) The Toronto Consensus Statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology 150(3):734–757.e1

    PubMed  Google Scholar 

  28. Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U (2018) Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. Gastroenterology 155(3):696–704

    PubMed  Google Scholar 

  29. Pham-Huy A, Sadarangani M, Huang V, Ostensen M, Castillo E, Troster SM et al (2019) From mother to baby: antenatal exposure to monoclonal antibody biologics. Expert Rev Clin Immunol 15(3):221–229

    CAS  PubMed  Google Scholar 

  30. Komaki F, Komaki Y, Micic D, Ido A, Sakuraba A (2017) Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-α use in females with immune mediated diseases; a systematic review and meta-analysis. J Autoimmun 76:38–52

    PubMed  Google Scholar 

  31. Bitter H, Bendvold AN, Østensen ME (2018) Lymphocyte changes and vaccination response in a child exposed to belimumab during pregnancy. Ann Rheum Dis 77(11):1692–1693

    CAS  PubMed  Google Scholar 

  32. Kumthekar A, Abhijeet D, Deodhar A (2013) Use of belimumab throughout 2 consecutive pregnancies in a patient with systemic lupus erythematosus. J Rheumatol 40(6):1–3

    Google Scholar 

  33. Danve A, Perry L, Deodhar A (2015) Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus—a case report. Semin Arthritis Rheum 44(2):195–197

    Google Scholar 

  34. Wallace DJ, Navarra S, Petri MA, Gallacher A, Thomas M, Furie R et al (2013) Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus 22(2):144–154

    CAS  PubMed  Google Scholar 

  35. Emmi G, Silvestri E, Squatrito D, Mecacci F, Ciampalini A, Emmi L et al (2016) Favorable pregnancy outcome in a patient with systemic lupus erythematosus treated with belimumab: a confirmation report. Semin Arthritis Rheum 45(6):e26–e27

    PubMed  Google Scholar 

  36. Sandhu VK, Wallace DJ, Weisman MH (2015) Monoclonal antibodies, systemic lupus erythematosus, and pregnancy: insights from an open-label study. J Rheumatol 42(4):4–6

    Google Scholar 

  37. Bazzani C, Scrivo R, Andreoli L, Baldissera E, Biggioggero M, Canti V et al (2015) Prospectively-followed pregnancies in patients with inflammatory arthritis taking biological drugs: an Italian multicentre study. Clin Exp Rheumatol 33(5):688–693

    PubMed  Google Scholar 

  38. Abisror N, Mekinian A, Brechignac S, Ruffatti A, Carbillon L, Fain O (2015) Inefficacy of plasma exchanges associated to rituximab in refractory obstetrical antiphospholipid syndrome. Press Med 44(1):100–102

    Google Scholar 

  39. Tsao NW, Lynd LD, Sadatsafavi M, Hanley G, De Vera MA (2018) Patterns of biologics utilization and discontinuation before and during pregnancy in women with autoimmune diseases: a population-based cohort study. Arthritis Care Res 70(7):979–986

    Google Scholar 

  40. Andreoli L, Bazzani C, Taraborelli M, Reggia R, Lojacono A, Brucato A et al (2010) Pregnancy in autoimmune rheumatic diseases: the importance of counselling for old and new challenges. Autoimmun Rev 10(1):51–54

    PubMed  Google Scholar 

  41. Conduit C, Yew S, Jose S, Jayne J, Kirkland G (2017) A case of de novo diagnosis antineutrophil cytoplasmic antibody negative pauci-immune necrotising glomerulonephritis in pregnancy. Intern Med J 47(5):593–600

    Google Scholar 

  42. Arce-Salinas CA, Rodríguez-García F, Gómez-Vargas JI (2012) Long-term efficacy of anti-CD20 antibodies in refractory lupus nephritis. Rheumatol Int 32(5):1245–1249

    CAS  PubMed  Google Scholar 

  43. Bröms G, Haerskjold A, Granath F, Kieler H, Pedersen L, Berglind IA (2018) Effect of maternal psoriasis on pregnancy and birth outcomes: a population-based cohort study from Denmark and Sweden. Acta Derm Venereol 98(8):728–734

    PubMed  Google Scholar 

  44. Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D (2012) Spontaneous abortion during ustekinumab therapy. J Dermatol Case Rep 6(4):105–107

    PubMed  PubMed Central  Google Scholar 

  45. Lund T, Thomsen SF (2017) Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: a patient series. Dermatol Ther 30(3):1–5

    Google Scholar 

  46. Cortes X, Borrás-Blasco J, Antequera B, Fernandez-Martinez S, Casterá E, Martin S et al (2017) Ustekinumab therapy for Crohn’s disease during pregnancy: a case report and review of the literature. J Clin Pharm Ther 42(2):234–236

    CAS  PubMed  Google Scholar 

  47. Echeverría-García B, Nuño-González A, Dauden E, Vanaclocha F, Torrado R, Belinchón I et al (2017) A case series of patients with psoriasis exposed to biologic therapy during pregnancy: the BIOBADADERM Register and a review of the literature. Actas Dermosifiliogr 108(2):168–170

    PubMed  Google Scholar 

  48. Beaulieu DB, Ananthakrishnan AN, Martin C, Cohen RD, Kane SV, Mahadevan U (2018) Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin Gastroenterol Hepatol 16(1):99–105

    PubMed  Google Scholar 

  49. Alsenaid A, Prinz JC (2016) Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis. J Eur Acad Dermatol Venereol. 30(3):488–490

    CAS  PubMed  Google Scholar 

  50. Galli-Novak E, Mook S-C, Buning J, Schmidt E, Zillikens D, Thaci D et al (2016) Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn’s disease and paradoxical psoriasis. J Eur Acad Dermatol Venereol 30(12):e189–e191

    Google Scholar 

  51. Da Rocha K, Piccinin MC, Kalache LF, Reichert-Faria A, Silva De Castro CC (2015) Pregnancy during ustekinumab treatment for severe psoriasis. Dermatology 231(2):103–104

    PubMed  Google Scholar 

  52. Sheeran C, Nicolopoulos J (2014) Pregnancy outcomes of two patients exposed to ustekinumab in the first trimester. Australas J Dermatol 55(3):235–236

    PubMed  Google Scholar 

  53. Youngstein T, Hoffmann P, Gül A, Lane T, Williams R, Rowczenio DM et al (2017) International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. Rheumatology (Oxford) 56(12):2102–2108

    Google Scholar 

  54. Smith CJF, Chambers CD (2018) Five successful pregnancies with antenatal anakinra exposure. Rheumatology (Oxford) 57(7):1271–1275

    CAS  Google Scholar 

  55. Fischer-Betz R, Specker C, Schneide M (2011) Successful outcome of two pregnancies in patients with adult-onset Still’s disease treated with IL-1 receptor antagonist (anakinra). Clin Exp Rheumatol 29(6):1021–1023

    PubMed  Google Scholar 

  56. Saito J, Yakuwa N, Takai C, Nakajima K, Kaneko K, Goto M et al (2018) Tocilizumab concentrations in maternal serum and breast milk during breastfeeding and a safety assessment in infants: a case study. Rheumatology (Oxford) 57(8):1499–1500

    CAS  Google Scholar 

  57. Weber-Schoendorfer C, Schaefer C (2016) Pregnancy outcome after tocilizumab therapy in early pregnancy-case series from the German Embryotox Pharmacovigilance Center. Reprod Toxicol 60:29–32

    CAS  PubMed  Google Scholar 

  58. Tan BE, Lim AL, Kan SL, Lim CH, Tsang EEL, Ch’ng SS et al (2017) Real-world clinical experience of biological disease modifying anti-rheumatic drugs in Malaysia rheumatoid arthritis patients. Rheumatol Int 37(10):1719–1725

    CAS  PubMed  Google Scholar 

  59. Kaneko K, Sugitani M, Goto M, Murashima A (2016) Tocilizumab and pregnancy: four cases of pregnancy in young women with rheumatoid arthritis refractory to anti-TNF biologics with exposure to tocilizumab. Mod Rheumatol 26(5):672–675

    CAS  PubMed  Google Scholar 

  60. Hoeltzenbein M, Beck E, Rajwanshi R, Gøtestam Skorpen C, Berber E, Schaefer C et al (2016) Tocilizumab use in pregnancy: analysis of a global safety database including data from clinical trials and post-marketing data. Semin Arthritis Rheum 46(2):238–245

    CAS  PubMed  Google Scholar 

  61. Nakajima K, Watanabe O, Mochizuki M, Nakasone A, Ishizuka N, Murashima A (2016) Pregnancy outcomes after exposure to tocilizumab: a retrospective analysis of 61 patients in Japan. Mod Rheumatol 26(5):667–671

    CAS  PubMed  PubMed Central  Google Scholar 

  62. Warren RB, Reich K, Langley RG, Strober B, Gladman D, Deodhar A et al (2018) Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. Br J Dermatol 179(5):1205–1207

    CAS  PubMed  Google Scholar 

  63. Strober B, Leonardi C, Papp KA, Mrowietz U, Ohtsuki M, Bissonnette R et al (2017) Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: etanercept comparisons and integrated data. J Am Acad Dermatol 76:432

    CAS  PubMed  Google Scholar 

  64. Kumar M, Ray L, Vemuri S, Simon TA (2015) Pregnancy outcomes following exposure to abatacept during pregnancy. Semin Arthritis Rheum 45(3):351–356

    CAS  PubMed  Google Scholar 

  65. Ojeda-Uribe M, Afif N, Dahan E, Sparsa L, Haby C, Sibilia J et al (2013) Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol 32(5):695–700

    PubMed  Google Scholar 

  66. Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber K et al (2016) BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-part II: analgesics and other drugs used in rheumatology practice. Rheumatology (Oxford) 55:1698

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Rheumatology Research, Rayne Institute, University College London (UCL), London, UK

    Hanh Nguyen & Ian Giles

  2. Department of Rheumatology, University College London Hospital, London, UK

    Ian Giles

Authors
  1. Hanh Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ian Giles
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ian Giles .

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, PGIMER, Chandigarh, India

    Shefali Khanna Sharma

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Nguyen, H., Giles, I. (2020). Update on Use of Biologic and Targeted Synthetic Drugs in Pregnancy. In: Sharma, S. (eds) Women's Health in Autoimmune Diseases. Springer, Singapore. https://doi.org/10.1007/978-981-15-0114-2_7

Download citation

  • DOI: https://doi.org/10.1007/978-981-15-0114-2_7

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-15-0113-5

  • Online ISBN: 978-981-15-0114-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation